secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-10-15T23:59:59+00:00
Accession:  0001193125-25-240237
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics raises ~$316M in public offering of 17M shares at $18.50
---------------------------------------------------------------------------

- Sold 14,864,865 shares at $18.50; underwriters exercised option for 2,229,729 additional shares.
- Gross proceeds of approximately $316.2 million before underwriting discounts and expenses.
- Net proceeds to fund IBD and rheumatic disease programs, including clinical trials and Phase 3 readiness.
- Underwriters include Jefferies, TD Securities, Leerink Partners, and Stifel; offering closed Oct 15, 2025.
- Offering was made under existing effective shelf registration statement (File No. 333-285341).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525240237/0001193125-25-240237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525240237/d40269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-240237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer